Immunohistochemical analysis of BRAF(V600E) expression of primary and metastatic melanoma and comparison with mutation status and melanocyte differentiation antigens of metastatic lesions.
about
Emerging clinical applications of selected biomarkers in melanomaConsensus guidelines for the diagnosis and clinical management of Erdheim-Chester diseaseDetection of the BRAF V600E mutation in colon carcinoma: critical evaluation of the imunohistochemical approachValidation of the VE1 immunostain for the BRAF V600E mutation in melanoma.Tumor homogeneity between primary and metastatic sites for BRAF status in metastatic melanoma determined by immunohistochemical and molecular testingImmunohistochemical detection of the BRAF V600E mutant protein in colorectal neoplasmsNRAS (Q61R), BRAF (V600E) immunohistochemistry: a concomitant tool for mutation screening in melanomas.Utility of BRAF V600E Immunohistochemistry Expression Pattern as a Surrogate of BRAF Mutation Status in 154 Patients with Advanced MelanomaTumor cellularity as a quality assurance measure for accurate clinical detection of BRAF mutations in melanoma.In situ Protein Detection for Companion Diagnostics.Concomitant KIT/BRAF and PDGFRA/BRAF mutations are rare events in gastrointestinal stromal tumorsThe utility of immunohistochemistry for providing genetic information on tumors.Current Understanding of BRAF Alterations in Diagnosis, Prognosis, and Therapeutic Targeting in Pediatric Low-Grade Gliomas.Immunohistochemical detection of the BRAF V600E mutation in melanoma patients with monoclonal antibody VE1.Melanocytic naevi with globular and reticular dermoscopic patterns display distinct BRAF V600E expression profiles and histopathological patterns.Comparison of high resolution melting analysis, pyrosequencing, next generation sequencing and immunohistochemistry to conventional Sanger sequencing for the detection of p.V600E and non-p.V600E BRAF mutations.BRAF V600E-specific immunohistochemistry reveals low mutation rates in biliary tract cancer and restriction to intrahepatic cholangiocarcinoma.Intratumor and Intertumor Heterogeneity in Melanoma.The significance of BRAF V600E mutation status discordance between primary cutaneous melanoma and brain metastases: The implications for BRAF inhibitor therapy.BRAF, NRAS, and GNAQ Mutations in Conjunctival Melanocytic Nevi.A comparison of immunohistochemical and molecular methods used for analyzing the BRAF V600E gene mutation in malignant melanoma in Taiwan.Utility of BRAF V600E mutation-specific immunohistochemistry in detecting BRAF V600E-mutated gastrointestinal stromal tumors.Discordancy in BRAF mutations among primary and metastatic melanoma lesions: clinical implications for targeted therapy.Immunohistochemical analysis of molecular drivers in melanoma identifies p16 as an independent prognostic biomarker.Immunohistochemistry as a quick screening method for clinical detection of BRAF(V600E) mutation in melanoma patients.Why and how immunohistochemistry should now be used to screen for the BRAFV600E status in metastatic melanoma? The experience of a single institution (LCEP, Nice, France).The diagnostic role and clinical relevance of determination of BRAF status in brain tumors.Molecular pathology of cutaneous melanoma
P2860
Q28087169-1F9B3FFA-81EA-4DA3-BF61-56C7092F580AQ28240576-A8AA55D9-BCA7-49BD-83E2-55F0E81C7DE1Q34052740-88D124C1-FEAF-45FC-8433-20558759CD4EQ34207132-A5C879FD-0875-4E73-A58E-E2F62BFFDD5BQ34970350-CD0C9620-75E5-4BFA-86D1-22A742380891Q35527097-20437E52-409B-407D-B810-69ACE5D41D98Q35885523-45231304-E91F-4322-829F-B5C7D3907B86Q35889462-1614E3F0-C5BC-4B8C-B12C-24339907CEE0Q36276146-B0EE4E63-D044-465C-A0EF-D108BC73E046Q37270405-C73683A2-1423-45AA-92AD-7E285CD7BA6FQ37327430-C4F87BCD-5FA4-4845-B114-2737D50FE707Q38142818-4A110645-568D-4848-B7EB-6085EDE45E8AQ38382607-87743F8C-DA8A-4C99-9985-851319A7BAAFQ39105498-75E62BEF-E509-45B5-A402-4C44ED6D1D12Q39157527-1FBAE10F-12E4-41F9-A727-AFC0FCBB0DFBQ41874659-28DEEE9E-6829-45FC-AF3E-3F209B98EE8AQ46509671-2C1A74ED-ADA8-41CD-A5C7-665E7D238B94Q46742817-E061D67F-7D7A-485E-8601-A0EAE23F03FDQ47105677-4A28C15C-3612-4CCA-940E-960EB3035FE8Q50053521-22AD8CCE-0D15-4AC3-B4B6-7C230A0B622EQ51595959-287C2378-BFAA-4982-9037-8C4E41739318Q52908238-DDB6CF00-ED0C-47E0-81E0-F57A26583C7CQ54311181-AFD1A459-D045-41E2-8A92-D60C6FB37786Q54372069-94AD14DC-E5A3-46E8-A1E5-E26BFB02FF00Q54375442-A942B7BB-7AE7-40CB-A17F-86D242CACA19Q55042787-C962718D-36D7-46BE-B9EF-6D0222AAEBC6Q55461604-E804D6DA-AF3D-4D8E-9904-1035C709E10CQ56428911-D42EE442-7051-4552-84D8-A07188EE0132
P2860
Immunohistochemical analysis of BRAF(V600E) expression of primary and metastatic melanoma and comparison with mutation status and melanocyte differentiation antigens of metastatic lesions.
description
2013 nî lūn-bûn
@nan
2013 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի մարտին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Immunohistochemical analysis of BRAF
@nl
Immunohistochemical analysis o ...... ntigens of metastatic lesions.
@ast
Immunohistochemical analysis o ...... ntigens of metastatic lesions.
@en
type
label
Immunohistochemical analysis of BRAF
@nl
Immunohistochemical analysis o ...... ntigens of metastatic lesions.
@ast
Immunohistochemical analysis o ...... ntigens of metastatic lesions.
@en
prefLabel
Immunohistochemical analysis of BRAF
@nl
Immunohistochemical analysis o ...... ntigens of metastatic lesions.
@ast
Immunohistochemical analysis o ...... ntigens of metastatic lesions.
@en
P2093
P1476
Immunohistochemical analysis o ...... ntigens of metastatic lesions.
@en
P2093
Cyrus Hedvat
Klaus J Busam
Melissa Pulitzer
P304
P356
10.1097/PAS.0B013E318271249E
P407
P577
2013-03-01T00:00:00Z